Analysts Estimate Buzz in Focus: Broadcom Limited (NASDAQ:AVGO), Yandex N.V. (NASDAQ:YNDX)

Broadcom Limited (NASDAQ:AVGO) [Trend Analysis] luring active investment momentum, shares a gain 0.48% to $206.89. Finally to see some strong financial remarks by WSJ over AVGO performance. Out of the pool of analysts 25 gave their BUY ratings on the stock in previous month as 24 analysts having BUY in current month. Majority ranked Buy from the pool of analysts.

Broadcom Limited (AVGO) reported that it will report its first quarter fiscal year 2017 financial results and business outlook on Wednesday, March 1, 2017 after the close of the market. Broadcom’s management will host a conference call at 2:00 p.m. Pacific Time on the same day to discuss these results and business outlook.

The next year first quarter EPS estimates trend for current period shows $3.47 while one month ago this estimate trend was for $3.47. EPS indicator shows the robustness of the stock and its analysis opens up the clear picture of company’s profitability. On annual basis of EPS, FY 2017 Estimate Trends at current were for $15.33 and for the one month was for $15.37 as compared to three months ago was for $14.67. Whereas, AVGO received highest price target of 250 and low target of 176. The stock price target chart showed average price target of 216.32 as compared to current price of 206.89.

The total volume of 2.11 Million shares held in the session was surprisingly higher than its average volume of 2980.42 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at -189.80%, and looking further price to next year’s EPS is 7.35%. While take a short look on price to sales ratio, that was 6.23.

Several matter pinch shares of Yandex N.V. (NASDAQ:YNDX) [Trend Analysis], as shares plunging -0.43% to $23.05 with a share volume of 1.66 Million. Finally, analysts shed their light over the YNDX price targets; maintaining price high target of 31 while at average the price target was 24.05 in contrast with the current price of 23.05. The price targets are usually acts as the boosters or blasters in the performance of stock. A higher price target would definitely provide confidence to investors during the trading action, consideration given by Wall Street Journal.

So does the rankings given by analysts; let us highlight rankings table and we had 6 analysts recommending BUY ratings for current month and for previous month 12 stands on similar situation; while 5 for the current month as compared to 3 analysts recommending for HOLD from the pool for previous month. While 1 out of pool consider it as Sell for current month. For the overall, consensus ratings were for Overweight.

The stock is going forward its 52-week low with 87.55% and moving down from its 52-week high price with -3.44%. To have technical analysis views, liquidity ratio of a company was calculated 6 as evaluated with its debt to equity ratio of 0.30. The float short ratio was 0.83%, as compared to sentiment indicator; Short Ratio was 1.01.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *